Christophe Douat
Chief Executive Officer bei MEDINCELL S.A.
Vermögen: 7 Mio $ am 31.03.2024
Profil
Christophe Douat is the founder and Chief Executive Officer of MedinCell SA, which was founded in 2003.
He is also the founder of Matignon Technologies II FCPR.
Currently, he holds the position of Chairman at Great North SARL and Director at CM Biomaterials BV.
In the past, he has held positions as Director-Stakes at Matignon Investissement et Gestion SAS from 2001 to 2010, Director at Arterial Remodelling Technologies SA, and Director at Groupement International d'Informatique de Santé SA. He was also a Member-Supervisory Board at Nanobiotix SA from 2011 to 2017 and from 2006 to 2009.
Additionally, he served as the General Manager at Sabourin Lake Lodge from 1992 to 1997 and as a Venture Partner at Matignon Technologies from 2001 to 2009.
Mr. Douat has a graduate degree from the University of Minnesota, an MBA from the University of Calgary, and an undergraduate degree from École Nationale Supérieure des Mines de Paris.
Mr. Douat is also the founder of Matignon Technologies II FCPR.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MEDINCELL SA
2,25% | 31.03.2023 | 652 916 ( 2,25% ) | 7 Mio $ | 31.03.2024 |
Aktive Positionen von Christophe Douat
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDINCELL S.A. | Chief Executive Officer | 09.01.2003 |
| Great North SARL | Chairman | - |
CM Biomaterials BV
 CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing CM Biomaterials BV is a Dutch company that manufactures plastic products. The joint venture company is based in Gorinchem, Netherlands. | Director/Board Member | - |
Ehemalige bekannte Positionen von Christophe Douat
| Unternehmen | Position | Ende |
|---|---|---|
| NANOBIOTIX | Director/Board Member | 01.01.2017 |
Matignon Investissement et Gestion SAS
 Matignon Investissement et Gestion SAS Investment ManagersFinance Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific. | Private Equity Investor | 01.05.2010 |
| Matignon Technologies | Corporate Officer/Principal | 01.04.2009 |
| NANOBIOTIX | Director/Board Member | 01.01.2009 |
| Sabourin Lake Lodge | Corporate Officer/Principal | 01.01.1997 |
Ausbildung von Christophe Douat
| University of Minnesota | Graduate Degree |
| University of Calgary | Masters Business Admin |
| École Nationale Supérieure des Mines de Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NANOBIOTIX | Health Technology |
| MEDINCELL S.A. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Matignon Investissement et Gestion SAS
Matignon Investissement et Gestion SAS Investment ManagersFinance Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific. | Finance |
Matignon Technologies II FCPR
 Matignon Technologies II FCPR Investment ManagersFinance Matignon Technologies II FCPR invests in early to later-stage companies mostly located in France and the European Union. It focuses on companies in the medical field or in the information technology sectors with revenues below €50 million. It invests between €500,000 and €10 million from early stage to growth operations. | Finance |
Arterial Remodelling Technologies SA
 Arterial Remodelling Technologies SA Pharmaceuticals: MajorHealth Technology Arterial Remodelling Technologies SA develops bioresorbable peripheral and coronary polymer stents. Its products includes ART PBS scaffold, procedure and Clinical data. The company was founded by Antoine Lafont, Michel Vert and J. Frederick Cornhill in 2001 and is headquartered in Paris, France. | Health Technology |
Groupement International d'Informatique de Santé SA
 Groupement International d'Informatique de Santé SA Publishing: Books/MagazinesConsumer Services Groupement International d'Informatique de Santé SA engages in the management of an online health and nutrition portal. Its services include daily effectiveness index, weekly synthesis, dietitian consultation, LeDiet community, practical tools, and chef and LeDiet recipes. The company was founded on October 9, 1986 and is headquartered in Paris, France. | Consumer Services |
| Great North SARL | |
CM Biomaterials BV
CM Biomaterials BV Miscellaneous ManufacturingProducer Manufacturing CM Biomaterials BV is a Dutch company that manufactures plastic products. The joint venture company is based in Gorinchem, Netherlands. | Producer Manufacturing |
| Sabourin Lake Lodge | |
| Matignon Technologies |
